All Stories

  1. A repeat offender: Recurrent extraintestinal Clostridium difficile infection following fecal microbiota transplantation
  2. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation
  3. Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin
  4. Absolute Lymphocyte Count: A Predictor of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients
  5. Evaluation of a two-stage testing algorithm for the diagnosis of respiratory viral infections
  6. Evaluation of theIn VitroActivity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates
  7. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
  8. Lyme disease
  9. Iron-related markers are associated with infection after liver transplantation
  10. Role of Secondary Prophylaxis With Valganciclovir in the Prevention of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients
  11. Selective method for identification and quantification of Bifidobacterium animalis subspecies lactis BB-12 (BB-12) from the gastrointestinal tract of healthy volunteers ingesting a combination probiotic of BB-12 and Lactobacillus rhamnosus GG
  12. Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010–2012 with comparison to 2008–2009
  13. Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients
  14. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
  15. In VitroEvaluation of the Activity of Imipenem-Relebactam against 451 Recent Clinical Isolates of Bacteroides Group and Related Species
  16. Increasing Infectious Endocarditis Admissions Among Young People Who Inject Drugs
  17. Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients
  18. Characteristics and outcomes of neutropenia after orthotopic liver transplantation
  19. Editorial Commentary : Chronic Lung Allograft Dysfunction in Lung Transplant Recipients: Another Piece of the Puzzle
  20. Physician report cards and rankings yield long-lasting hand hygiene compliance exceeding 90 %
  21. U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin
  22. Effect of Lactobacillus rhamnosus GG Administration on Vancomycin-Resistant Enterococcus Colonization in Adults with Comorbidities
  23. Risk and Safety of Probiotics
  24. In vitro evaluation of cytomegalovirus‐specific hyperimmune globulins vs. standard intravenous immunoglobulins
  25. No Evidence of Harms of Probiotic Lactobacillus rhamnosus GG ATCC 53103 in Healthy Elderly—A Phase I Open Label Study to Assess Safety, Tolerability and Cytokine Responses
  26. A national survey of infectious disease practitioners on their use of outpatient parenteral antimicrobial therapy (OPAT)
  27. Horizontal Infection Control Strategy Decreases Methicillin-Resistant Staphylococcus aureus Infection and Eliminates Bacteremia in a Surgical ICU Without Active Surveillance*
  28. Pretransplant Lymphopenia is a Novel Prognostic Factor in CMV and Non-CMV Invasive Infection After Liver Transplantation
  29. Carbapenem-resistant enterobacteriaceae: analyzing knowledge and practice in healthcare providers
  30. Editorial Commentary: The Complexity of Latent Cytomegalovirus Infection in Stem Cell Donors
  31. The Efficacy of Daptomycin Versus Vancomycin for Methicillin-Resistant Staphylococcus aureus Bloodstream Infection in Patients With Impaired Renal Function
  32. Muldoon et al (Clin Infect Dis 2013; 57:419-24)
  33. Prediction Model for 30-Day Hospital Readmissions Among Patients Discharged Receiving Outpatient Parenteral Antibiotic Therapy
  34. The impact of cefepime as first line therapy for neutropenic fever on Clostridium difficile rates among hematology and oncology patients
  35. Activity of Ceftolozane-Tazobactam against a Broad Spectrum of Recent Clinical Anaerobic Isolates
  36. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
  37. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
  38. Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation
  39. Infections in Children and Adolescents With Juvenile Idiopathic Arthritis and Inflammatory Bowel Disease Treated With Tumor Necrosis Factor-  Inhibitors: Systematic Review of the Literature
  40. Rare and Emerging Viral Infections in Transplant Recipients
  41. Outpatient parenteral antimicrobial therapy (OPAT) in the republic of Ireland: results of a national survey
  42. A Nationwide Survey of Antimicrobial Stewardship Practices
  43. Are We Ready for an Outpatient Parenteral Antimicrobial Therapy Bundle? A Critical Appraisal of the Evidence
  44. Vancomycin-ResistantEnterococcusInfections in Solid Organ Transplantation
  45. Neutropenic Enterocolitis, a Growing Concern in the Era of Widespread Use of Aggressive Chemotherapy
  46. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
  47. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
  48. State-of-the-Art Monitoring of Cytomegalovirus-Specific Cell-Mediated Immunity After Organ Transplant: A Primer for the Clinician
  49. First report of a left ventricular assist device infection caused by Staphylococcus schleiferi subspecies coagulans: a coagulase-positive organism
  50. Carbapenem-Resistant Enterobacteriaceae: A Statewide Survey of Detection in Massachusetts Hospitals
  51. Transmission of Infection With Human Allografts: Essential Considerations in Donor Screening
  52. Nosocomial Hepatitis C: More of a Hidden Epidemic
  53. Activity of a Novel Cyclic Lipopeptide, CB-183,315, against Resistant Clostridium difficile and Other Gram-Positive Aerobic and Anaerobic Intestinal Pathogens
  54. Empiric antibiotic selection strategies for healthcare-associated pneumonia, intra-abdominal infections, and catheter-associated bacteremia
  55. Reply to van Hal et al
  56. Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006–2009
  57. High Incidence of Herpes Zoster in Nonmyeloablative Hematopoietic Stem Cell Transplantation
  58. Persistent babesiosis in a stem cell transplant recipient
  59. The impact of CMV prevention on long-term recipient and graft survival in heart transplant recipients: analysis of the Scientific Registry of Transplant Recipients (SRTR) database
  60. Why did maribavir fail in stem-cell transplants?
  61. Update and Review: State-of-the-Art Management of Cytomegalovirus Infection and Disease Following Thoracic Organ Transplantation
  62. Predicting High Vancomycin Minimum Inhibitory Concentration in Methicillin-Resistant Staphylococcus aureus Bloodstream Infections
  63. Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial
  64. Putting the IMPACT Study into Perspective: Should CMV Prophylaxis Be Extended to 6 Months for High Risk Transplants?
  65. Cytomegalovirus Prevention and Long-Term Recipient and Graft Survival in Pediatric Heart Transplant Recipients
  66. In VitroActivity of Ceftaroline against a Broad Spectrum of Recent Clinical Anaerobic Isolates
  67. Leflunomide: A Small Step Forward in Meeting the Urgent Need for Treatment of Drug-Resistant Cytomegalovirus Infection
  68. Increased Serum Iron Levels and Infectious Complications after Liver Transplantation
  69. Blood stream infection (BSI) and acute GVHD after hematopoietic SCT (HSCT) are associated
  70. A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4 to 24 after BMT
  71. International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation
  72. Evaluation of Vancomycin and Daptomycin Potency Trends (MIC Creep) against Methicillin-Resistant Staphylococcus aureus Isolates Collected in Nine U.S. Medical Centers from 2002 to 2006
  73. Donor Screening for Human T-cell Lymphotrophic Virus 1/2: Changing Paradigms for Changing Testing Capacity
  74. Introduction
  75. Lessons Learned from the Anaerobe Survey: Historical Perspective and Review of the Most Recent Data (2005–2007)
  76. Cytomegalovirus in Solid Organ Transplant Recipients
  77. Severity of illness scoring systems in patients with bacteraemic pneumococcal pneumonia: implications for the intensive care unit care
  78. Evaluation of Vancomycin and Daptomycin Potency Trends (MIC Creep) against Methicillin-Resistant Staphylococcus aureus Isolates Collected in Nine U.S. Medical Centers from 2002 to 2006
  79. Cytomegalovirus Prevention Strategies: The Case for Prophylaxis
  80. Risk factors for death after sepsis in patients immunosuppressed before the onset of sepsis
  81. In Vitro Activities of Doripenem, a New Broad-Spectrum Carbapenem, against Recently Collected Clinical Anaerobic Isolates, with Emphasis on the Bacteroides fragilis Group
  82. Editorial Commentary: Persistent Clinical Impact of Cytomegalovirus in Organ Transplantation
  83. Antibiotic Exposure and Room Contamination Among Patients Colonized With Vancomycin-Resistant Enterococci
  84. Destruction of Isolates from the Pittsburgh Veterans Affairs Laboratory
  85. Prior Environmental Contamination Increases the Risk of Acquisition of Vancomycin-Resistant Enterococci
  86. The Safety of Probiotics
  87. Repeated enzyme immunoassays have limited utility in diagnosing Clostridium difficile
  88. Use of Valganciclovir for Prevention and Treatment of Cytomegalovirus Disease
  89. Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: current approach and future challenges
  90. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients
  91. Prevention of Catheter-Related Bloodstream Infections: Looking to the Department of Veterans Affairs Health Care System for Guidance
  92. Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality
  93. National Survey on the Susceptibility of Bacteroides fragilis Group: Report and Analysis of Trends in the United States from 1997 to 2004
  94. Preventing Post–Organ Transplantation Cytomegalovirus Disease with Ganciclovir: A Meta‐Analysis Comparing Prophylactic and Preemptive Therapies
  95. Prevention of Catheter and Intravascular Device-Related Infections: A Quality-of-Care Mandate for Institutions and Physicians
  96. Endocarditis and pericarditis complicating pneumococcal bacteraemia, with special reference to the adhesive abilities of pneumococci: results from a prospective study
  97. Hypogammaglobulinemia in Liver Transplant Recipients: Incidence, Timing, Risk Factors, and Outcomes
  98. Multicenter Evaluation of the In Vitro Susceptibility of Staphylococci to Vancomycin
  99. The Impact of Gown-Use Requirement on Hand Hygiene Compliance
  100. The potential role for iron overload and fungal infection in liver transplantation
  101. The case for cytomegalovirus prophylaxis in solid organ transplantation
  102. Lactobacillus GG: Bacteriology and Clinical Applications
  103. Fluconazole MIC and the Fluconazole Dose/MIC Ratio Correlate with Therapeutic Response among Patients with Candidemia
  104. The Clinical Relevance and Correct Designation of Isolates Nonsusceptible to Daptomycin
  105. Transmission of Vancomycin-Resistant Enterococcus in a Neonatal Intensive Care Unit
  106. Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group
  107. Daptomycin‐Resistant, Methicillin‐Resistant Staphylococcus aureus Bacteremia
  108. Counterpoint: Prevention of Cytomegalovirus (CMV) Infection and CMV Disease in Recipients of Solid Organ Transplants: The Case for Prophylaxis
  109. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation
  110. The Clinical Impact of Ganciclovir Prophylaxis on the Occurrence of Bacteremia in Orthotopic Liver Transplant Recipients
  111. Combination Antibiotic Therapy Lowers Mortality among Severely Ill Patients with Pneumococcal Bacteremia
  112. Iron storage indices and risk of bacterial infections in hemodialysis patients
  113. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy
  114. Iron Storage Indices: Novel Predictors of Bacteremia in Hemodialysis Patients Initiating Intravenous Iron Therapy
  115. In Vitro Activities of Tigecycline against the Bacteroides fragilis Group
  116. Viral Prophylaxis in Organ Transplant Patients
  117. Relationship of pulmonary artery catheter use to mortality and resource utilization in patients with severe sepsis*
  118. Vancomycin-resistant enterococcal infections: Cause for concern?
  119. Role of Environmental Contamination as a Risk Factor for Acquisition of Vancomycin-Resistant Enterococci in Patients Treated in a Medical Intensive Care Unit
  120. An International Prospective Study of Pneumococcal Bacteremia: Correlation with In Vitro Resistance, Antibiotics Administered, and Clinical Outcome
  121. Emergence of fluoroquinolone resistance among Bacteroides species
  122. Shifting Patterns in the Epidemiology of Nosocomial Candida Infections*
  123. Randomized Comparison of Oral Valacyclovir and Intravenous Ganciclovir for Prevention of Cytomegalovirus Disease after Allogeneic Bone Marrow Transplantation
  124. Reduced Acquisition of Vancomycin‐Resistant Enterococci: Gown Effect or Confounding?
  125. In Vitro Activities of Newer Quinolones against Bacteroides Group Organisms
  126. Resource Utilization Among Patients With Sepsis Syndrome
  127. In Vitro Activities of Newer Quinolones against Bacteroides Group Organisms
  128. National Survey on the Susceptibility of Bacteroides fragilis Group: Report and Analysis of Trends for 1997–2000
  129. Association between the Presence of Enterococcal Virulence Factors Gelatinase, Hemolysin, and Enterococcal Surface Protein and Mortality among Patients with Bacteremia Due to Enterococcus faecalis
  130. Attributable Mortality of Stenotrophomonas maltophilia Bacteremia
  131. Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients
  132. GB Virus C and Mortality from HIV Infection
  133. Clinical utility of blood cultures drawn from central venous or arterial catheters in critically ill surgical patients
  134. Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation
  135. Association of Human Herpesvirus 6 Reactivation with Severe Cytomegalovirus‐Associated Disease in Orthotopic Liver Transplant Recipients
  136. Determinants of Vancomycin Resistance and Mortality Rates in Enterococcal Bacteremia: A Prospective Multicenter Study
  137. Late and Atypical Cytomegalovirus Disease in Solid‐Organ Transplant Recipients
  138. Posttransplant Microbiological Surveillance
  139. Epidemiology of Infections after Solid‐Organ Transplantation
  140. Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study
  141. Daptomycin for line-related Leuconostoc bacteraemia
  142. Increasing Mortality Due to End-Stage Liver Disease in Patients with Human Immunodeficiency Virus Infection
  143. Comparative In Vitro Activities of Daptomycin and Vancomycin against Resistant Gram-Positive Pathogens
  144. Clinical Manifestations and Molecular Epidemiology of Late Recurrent Candidemia, and Implications for Management
  145. Comparative In Vitro Activities of Clinafloxacin and Trovafloxacin against 1,000 Isolates of Bacteroides fragilisGroup: Effect of the Medium on Test Results
  146. Antimicrobial Resistance and Clinical Outcome of Bacteroides Bacteremia: Findings of a Multicenter Prospective Observational Trial
  147. Cytomegalovirus immune globulin after liver transplantation: a cost-effectiveness analysis 1
  148. Varicella zoster virus infections following allogeneic bone marrow transplantation: Frequency, risk factors, and clinical outcome
  149. Clinical Utility of Blood Cultures Drawn from Indwelling Central Venous Catheters in Hospitalized Patients with Cancer
  150. OUTCOME OF TRANSPLANTATION OF ORGANS PROCURED FROM BACTEREMIC DONORS1
  151. Infection in solid organ transplantation
  152. Human Herpesvirus 6 Reactivation Is Associated with Cytomegalovirus Infection and Syndromes in Kidney Transplant Recipients at Risk for Primary Cytomegalovirus Infection
  153. Utility of Serial Rectal Swab Cultures for Detection of Ceftazidime- and Imipenem-Resistant Gram-Negative Bacilli from Patients in the Intensive Care Unit
  154. SIGNIFICANCE OF CYTOMEGALOVIRUS FOR LONG-TERM SURVIVAL AFTER ORTHOTOPIC LIVER TRANSPLANTATION
  155. Limulus Amebocyte Lysate Assay for Detection of Endotoxin in Patients with Sepsis Syndrome
  156. Vaccine-Associated Measles Pneumonitis in an Adult with AIDS
  157. Vancomycin-resistant enterococcal infections in bone marrow transplant recipients
  158. ORGAN DONOR SCREENING FOR INFECTIOUS DISEASES
  159. Infective Endocarditis in Solid Organ Transplant Recipients
  160. Late Incidence of Cancer After Metronidazole Use: A Matched Metronidazole User/Nonuser Study
  161. Adenovirus Infection in Adult Orthotopic Liver Transplant Recipients: Incidence and Clinical Significance
  162. Antiviral Immunotherapy
  163. The Independent Role of Cytomegalovirus as a Risk Factor for Invasive Fungal Disease in Orthotopic Liver Transplant Recipients
  164. Clinical and Epidemiological Predictors of Recurrent Cytomegalovirus Disease in Orthotopic Liver Transplant Recipients
  165. Epidemiology of sepsis syndrome in 8 academic medical centers. Academic Medical Center Consortium Sepsis Project Working Group
  166. CYTOMEGALOVIRUS DISEASE IS ASSOCIATED WITH INCREASED COST AND HOSPITAL LENGTH OF STAY AMONG ORTHOTOPIC LIVER TRANSPLANT RECIPIENTS1
  167. Effect of Cytomegalovirus Infection Status on First-Year Mortality Rates among Orthotopic Liver Transplant Recipients
  168. Predicting Clostridium difficile Stool Cytotoxin Results in Hospitalized Patients with Diarrhea
  169. Predicting Clostridium difficile Stool Cytotoxin Results in Hospitalized Patients with Diarrhea
  170. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections
  171. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance
  172. INCIDENCE AND PREDICTORS OF CYTOMEGALOVIRUS PNEUMONIA IN ORTHOTOPIC LIVER TRANSPLANT RECIPIENTS1
  173. CYTOMEGALOVIRUS PROPHYLAXIS IN SOLID ORGAN TRANSPLANT RECIPIENTS
  174. Prevention of cytomegalovirus disease in transplant recipients
  175. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study
  176. Therapeutic Approaches in Patients With Candidemia
  177. Spectrum and Significance of Bacteremia Due to Moraxella catarrhalis
  178. Preemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Cytomegalovirus Antibody-Positive Renal Transplant Recipients
  179. Attributable Mortality of Bacteremia Associated with the Bacteroides fragilis Group
  180. Aspergillus fumigatus Infection of a Biloma
  181. Treatment of Severe Pneumonia in Hospitalised Patients
  182. Influence of Blood Culture Results on Antibiotic Choice in the Treatment of Bacteremia
  183. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.
  184. Cytomegalovirus Immune Globulin Prophylaxis in Liver Transplantation
  185. Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin.
  186. New Developments in Cytomegalovirus Prevention and Management
  187. Correlation of various in vitro testing methods with clinical outcomes in patients with Bacteroides fragilis group infections treated with cefoxitin: a retrospective analysis.
  188. The risk of cytomegalovirus infection in solid organ and bone marrow transplant recipients: transfusion of blood products
  189. Cytomegalovirus Immunoglobulins in the Prevention and Treatment of Cytomegalovirus Disease
  190. Capnocytophaga infection involving a portal-systemic vascular shunt
  191. Cytomegalovirus infection in solid organ transplantation: Prospects for prevention
  192. An Outbreak of Hepatitis A among Cancer Patients Treated with Interleukin-2 and Lymphokine-Activated Killer Cells
  193. Nosocomial Sepsis Associated with Interleukin-2
  194. The antimicrobial susceptibility patterns of the Barteroides fragilis group in the United States, 1987
  195. Nosocomial Branhamella catarrhalis in a paediatric intensive care unit: Risk factors for disease
  196. Ganciclovir Therapy for Cytomegalovirus Disease Associated with Renal Transplants
  197. Prevention of Nosocomial Transmission of Respiratory Syncytial Virus in a Newborn Nursery
  198. Ganciclovir for Treatment of Renal Transplant-Associated Primary Cytomegalovirus Pneumonia
  199. Use of Cytomegalovirus Immune Globulin to Prevent Cytomegalovirus Disease in Renal-Transplant Recipients
  200. Clinical importance of cefoxitin-resistant Bacteroides fragilis isolates
  201. Borrelia burgdorferi in Joint Fluid in Chronic Lyme Arthritis
  202. Hepatitis in Pregnancy
  203. Absence of antibodies to HTLV-III in health workers after hepatitis B vaccination
  204. Absence of Antibodies to HTLV-III in Health Workers After Hepatitis B Vaccination
  205. Isolated Antibody to Hepatitis B Surface Antigen and Response to Hepatitis B Vaccination
  206. Changing Intravenous Tubing Containing Burettes-Reply
  207. Capnocytophaga Species: Infections in Nonimmunocompromised and Immunocompromised Hosts
  208. Ocular and pericardial involvement in Legionnaires' disease
  209. Hepatitis B Vaccine in Health Care Personnel: Safety, lmmunogenicity, and Indicators of Efficacy
  210. Acquired Immunodeficiency Syndrome with Progressive Multifocal Leukoencephalopathy and Monoclonal B-Cell Proliferation
  211. A simultaneous outbreak of respiratory syncytial virus and parainfluenza virus type 3 in a newborn nursery
  212. Intravenous tubing with burettes can be safely changed at 48-hour intervals
  213. Intravenous Tubing With Burettes Can Be Safely Changed at 48-Hour Intervals
  214. Hemophilus aphrophilus osteomyelitis
  215. Prevention of Cytomegalovirus Infection by Cytomegalovirus Immune Globulin After Marrow Transplantation
  216. BACTERIA IN TOTAL PARENTERAL NUTRITION CATHETERS
  217. PREDICTIVE VALUE OF SURVEILLANCE SKIN CULTURES IN TOTAL-PARENTERAL-NUTRITION-RELATED INFECTION
  218. Total parenteral nutrition-related infections
  219. Infectious Mononucleosis in an Adult Progressing to Fatal lmmunoblastic Lymphoma
  220. Use of IgM-hepatitis A antibody testing. Investigating a common-source, food borne outbreak
  221. Use of IgM-Hepatitis A Antibody Testing
  222. Clinical trial of piperacillin with acquisition of resistance by Pseudomonas and clinical relapse.
  223. Bacteroides bivius and Bacteroides disiens in obstetrical patients: clinical findings and antimicrobial susceptibilities
  224. Antiviral Agents
  225. Netilmicin in Gram-Negative Bacterial Infections
  226. Plasmid-Mediated, Transferable Resistance to Clindamycin and Erythromycin in Bacteroides fragilis
  227. Sputum: a diagnostic pitfall in alcoholics
  228. Sputum
  229. An epidemic of oligoarticular arthritis in children and adults in three connecticut communities
  230. Transmission of Hepatitis B Associated with Hemodialysis: Role of Malfunction (Blood Leaks) in Dialysis Machines
  231. Nosocomial Viral Hepatitis B
  232. Hepatitis B infection from medical personnel
  233. Hepatitis B Infection From Medical Personnel
  234. Prevention of Nosocomial Viral Hepatitis, Type B (Hepatitis B)
  235. Thin-layer chromatography of citric acid cycle intermediates, pyruvate and lactate